This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Est. Enrollment: 18 participants
Study Start Date: Aug 31, 2021
Study Completion Date: Sep 01, 2025
Age: 18 to 70 years
Gender: All
Contact Us
A member of our team would love to assist you.
How Clinical Trials Work (800) 930-5159 Email usSubscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811